Transforaminal Epidural Injection in Acute Sciatica

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients suffering from sciatica are treated conservatively for the first 8 weeks due to the favourable prognosis. This period is preferably extended up to 14-16 weeks after which patients may opt for surgery. However, patients may experience severe discomfort due to pain in the leg which can lead to decreased physical activity and socio-economic problems. An adequate therapy to alleviate symptoms during this period of 'wait-and-see' is lacking. In this study, patients will be randomized to treatment with transforaminal epidural injections or standard oral pain medication.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: C.L.A.Vleggeert-Lankamp
• Collaborators: Posthumus Meyjes Fonds; Spaarne Gasthuis; Stichting Achmea Gezondheidszor
• Treatments: Dexamethasone; Lidocaine; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• Diagnosed with sciatica by GP

• NRS leg pain of 6 or more on a 10-point NRS scale

• Minimum duration of symptoms of 3 weeks and maximum duration of 8 weeks

Exclusion Criteria:

• Age under 18 years

• Condition preventing to receive transforaminal epidural injection

• Severe scoliosis

• Transforaminal epidural injection received in 6 months before randomization date

• Surgery for sciatica at the same level

• Surgery for sciatica at another level within one year before inclusion

• Pregnancy